The European Patent Office has issued and published the first European patent for a novel ovarian cancer vaccine technology. This technology was developed at Cleveland Clinic and California-based Anixa Biosciences, Inc. The patent is titled "Ovarian Cancer Vaccines," and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson of Cleveland Clinic, based in Ohio. Anixa is the worldwide licensee.
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
Technology invented and developed at Cleveland Clinic
News provided by
Share this article
Share this article
SAN JOSE, Calif., March 12, 2021 /PRNewswire/ Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.
The patent is titled, Ovarian Cancer Vaccines, and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic.